Vera Therapeutics grants 258,200 options, 131,925 RSUs at $40.33 to 89 hires
On April 8, Vera Therapeutics granted non-qualified stock options for 258,200 shares and RSUs underlying 131,925 shares to 89 new hires under its 2024 Inducement Plan. Options vest 25% after one year and monthly thereafter over four years at a $40.33 exercise price, while RSUs vest 25% annually.
1. Inducement Awards Details
On April 8, Vera Therapeutics’ Compensation Committee awarded non-qualified stock options to purchase 258,200 shares and restricted stock units underlying 131,925 shares to 89 new employees under the 2024 Inducement Plan.
2. Vesting Schedule
Each option carries a $40.33 exercise price, vesting 25% after one year with the remaining shares vesting monthly over the next 36 months; RSUs vest 25% annually over four years from May 20, 2026.
3. Strategic Implications
The inducement grants aim to attract and retain talent in late clinical-stage biotech operations, potentially enhancing workforce stability but contributing to future share dilution as awards vest.